...
首页> 外文期刊>Cancer Cell International >MicroRNA-214-3p inhibits proliferation and cell cycle progression by targeting MELK in hepatocellular carcinoma and correlates cancer prognosis
【24h】

MicroRNA-214-3p inhibits proliferation and cell cycle progression by targeting MELK in hepatocellular carcinoma and correlates cancer prognosis

机译:MicroRNA-214-3p通过靶向MELK抑制肝细胞癌的增殖和细胞周期进程,并与癌症预后相关

获取原文
           

摘要

MicroRNAs are considered as potential regulators in various biological pathways and contribute to the diagnosis and prognosis of cancers. MicroRNA-214-3p (miR-214-3p) was proved to be correlated with various cancers in recent studies. However, the biological functions of miR-214-3p in hepatocellular carcinoma (HCC) and its association with the prognosis of HCC after liver transplantation are still unevaluated. Here we intended to elucidate the functional implication of miR-214-3p in regulation of cell proliferation and apoptosis and its potential prediction of clinical prognosis of HCC patients. Expressions of miR-214-3p in 98 HCC patients and three HCC cell lines were detected by quantitative reverse transcription PCR (qRT-PCR) to explore the association of miR-214-3p expression and clinicopathological characteristics. The effects of miR-214-3p on cell proliferation and apoptosis were examined by proliferation and flow cytometry assay, respectively. The direct target gene of miR-214-3p was also detected by luciferase reporter assay. The effects of miR-214-3p on cell proliferation and apoptosis were examined by proliferation and flow cytometry assay, respectively. The direct target gene of miR-214-3p was also detected by luciferase reporter assay. The results showed that miR-214-3p expression was downregulated in primary HCC samples compared with normal liver tissues, and was decreased in HCC recurrence species compared with non-recurrence controls (P = 0.001). Low miR-214-3p level was associated with poor overall survival (OS) (Log rank P = 0.003) and recurrence-free survival (RFS) (Log rank P = 0.007). Moreover, miR-214-3p precursor transfection resulted in decreased cell proliferation, cell cycle arrest at G1 phase, and enhanced cell apoptosis in HepG2 and HUH-7 cells. Further investigation showed that miR-214-3p could regulate its target gene maternal embryonic leucine zipper kinase (MELK) by directly binding to MELK-3′-UTR. miR-214-3p suppresses HCC progression by directly down-regulating MELK expression, indicating a potential therapeutic target for the treatment and prognosis of HCC patients.
机译:MicroRNA被认为是各种生物学途径中的潜在调节剂,并有助于癌症的诊断和预后。在最近的研究中,MicroRNA-214-3p(miR-214-3p)被证明与多种癌症相关。然而,miR-214-3p在肝细胞癌(HCC)中的生物学功能及其与肝移植后HCC预后的关系仍未得到评估。在这里,我们打算阐明miR-214-3p在调节细胞增殖和凋亡中的功能含义及其对肝癌患者临床预后的潜在预测。通过定量逆转录PCR(qRT-PCR)检测98例HCC患者和3种HCC细胞株中miR-214-3p的表达,探讨miR-214-3p表达与临床病理特征的关系。分别通过增殖和流式细胞术检测miR-214-3p对细胞增殖和凋亡的影响。 miR-214-3p的直接靶基因也通过荧光素酶报告基因检测法检测。分别通过增殖和流式细胞术检测miR-214-3p对细胞增殖和凋亡的影响。 miR-214-3p的直接靶基因也通过荧光素酶报告基因检测法检测。结果表明,与正常肝组织相比,原发性HCC样品中的miR-214-3p表达下调,与非复发对照相比,HCC复发物种中的miR-214-3p表达降低(P = 0.001)。低miR-214-3p水平与较差的总体生存率(OS)(对数秩P = 0.003)和无复发生存期(RFS)(对数秩P = 0.007)相关。此外,miR-214-3p前体转染导致细胞增殖减少,G1期细胞周期停滞以及HepG2和HUH-7细胞的细胞凋亡增强。进一步的研究表明,miR-214-3p可以通过直接与MELK-3'-UTR结合来调节其靶基因母体胚胎亮氨酸拉链激酶(MELK)。 miR-214-3p通过直接下调MELK表达来抑制HCC进程,表明其是治疗和预后HCC患者的潜在靶点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号